<DOC>
	<DOCNO>NCT02295059</DOCNO>
	<brief_summary>The investigator study aim determine biological change associate low vs high dose omega 3 fatty acid , docosahexaenoic acid ( DHA ) , eicosapentaenoic acid ( EPA ) , 12 month woman risk recurrent breast cancer . The objective trial develop mammary epithelial , adipose tissue specific marker exposure response omega 3 fatty acid supplement carry forward definitive intervention trial omega 3 fatty acid breast cancer prevention . The investigator randomize 80 subject hormone receptor negative , HER-2/neu overexpression positive negative breast cancer either high low dose omega 3 fatty acid . Using fine needle aspiration procure cellular sample breast epithelial adipose tissue , investigator determine effect omega 3 fatty acid mammary specific biomarkers response .</brief_summary>
	<brief_title>Omega 3 Fatty Acids ERPR ( - ) HER2 ( +/- ) Breast Cancer Prevention</brief_title>
	<detailed_description>The investigator study aim determine biological change occur 12 month intervention low ( ~0.9 g EPA+DHA/day ) vs high dose ( ~5.4 g EPA+DHA/day ) omega 3 polyunsaturated fatty acid ( PUFAs ) woman survivor hormone unresponsive breast cancer . The objective trial develop unique mammary epithelial , adipose tissue specific marker exposure response omega 3 fatty acid supplement carry forward definitive intervention trial EPA , DHA/omega 3 PUFAs breast cancer prevention . The investigator randomize 80 subject hormone receptor negative , HER-2/neu overexpression positive negative breast cancer either high low dose omega 3 PUFAs . Using fine needle aspiration procure cellular sample breast epithelial adipose tissue , investigator determine effect omega 3 fatty acid mammary specific biomarkers response .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>Prior diagnosis Stage 0 III breast cancer estrogen receptor negative , progesterone receptor negative completion definitive surgery , radiation therapy and/or chemotherapy . Completion chemotherapy trastuzumab &gt; six month radiation therapy &gt; 2 month , applicable 5 year less completion standard therapy . Greater 1 year pregnancy , lactation . Mammogram within eight month prior study enrollment suspicious breast cancer ( ACR Class IIII ) . Other current malignancy metastatic malignancy kind . Ongoing chemotherapy , radiation therapy , cancerrelated treatment . Subjects Coumadin anticoagulant . Subjects breast implant . Subjects radiation breast undergone bilateral mastectomy . Barriers fine needle aspiration sample breast adipose tissue and/or parenchymal breast tissue , include breast implant , history radiation breast , bilateral mastectomy , and/or insufficient breast adipose/parenchymal tissue adequate fine needle aspiration ( FNA ) sample . Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , hypertension , psychiatric illness/social situation would limit compliance study requirement . Chronic use omega 3 fatty acid concentrate capsule within 3 month prior entry study supplement might interact omega 3 fatty acid supplement . Pregnant nursing woman . Known sensitivity allergy fish . Subjects stand regimen full dose aspirin ( great 325 mg/day ) , NSAIDs ( nonsteriodal anti inflammatory drug ) NSAIDcontaining product .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Breast cancer</keyword>
	<keyword>ERPR negative</keyword>
	<keyword>HER-2/neu overexpression positive negative</keyword>
</DOC>